<div><p><b>Background:</p> </b><p>Primary sclerosing cholangitis (PSC),<span> </span>a chronic cholangiopathy, results in cholestasis, inflammation, and stricturing of intrahepatic and extrahepatic bile ducts. Recently, we have shown that the transcription factor STAT3 mediated, in part, the protective role of the FXR agonist, GW4064, in parenteral nutrition (PN)-associated cholestasis <em>(Ghosh et al., Hep comm 2023)</em>.

<div><p><b>Background: </b>Hepatorenal syndrome type 1 (HRS-1) is a rapidly progressive form of renal failure associated with high mortality in patients (pts) with decompensated cirrhosis and ascites. The FDA-approved vasopressin analogue, terlipressin (terli), improves renal function in pts with HRS-1 by reducing portal hypertension and increasing effective arterial volume and mean arterial pressure (MAP)—a marker of the hemodynamic response to treatment.

<div><p><strong><b>Background:</strong> </b><span> </span><span> </span>Since our first pediatric anonymous non-directed live donor liver transplant (Anon-LDLT) performed in April 2005, 62 children have undergone live donor liver transplant (LDLT) with an anonymous non-directed graft. Anon-LDLT organs being allocated as per our deceased donor liver transplant wait list.

<div><p><b>Background:</p> </b><p style="font-weight: 400;">Peripheral blood (PB) regulatory T cells (Tregs) in post-transplant alloimmune hepatitis (DAIH) &amp; autoimmune hepatitis (AIH) have poor regulatory function, however little is known about intrahepatic (IH) Tregs in both diseases.

<div><p><b>Background: </b>During metabolic dysfunction-associated steatohepatitis (MASH), liver sinusoidal endothelial cells (LSECs) acquire a pro-inflammatory phenotype characterized by increased adhesion molecules expression and myeloid cells-associated liver inflammation culminating in disease progression. However, the exact molecular mediators of this phenomenon are unclear.

<div><p><b>Background: </b>Patients with decompensated cirrhosis are frequently hospitalized and often undergo multiple invasive procedures. We aimed to define the incidence of procedural-related bleeding in patients with acute on chronic liver failure (ACLF) and to compare it with that of patients without ACLF.</p>

<div><p><b>Background: </b>Detecting patients with undiagnosed chronic liver disease is a public health challenge. Patients with advanced fibrosis or compensated cirrhosis have much better outcomes than those with decompensated disease and may be eligible for interventions to prevent disease progression</p>

<div><p><b>Background:<span> </b>Chronic hepatitis B (CHB) suppressive therapy with tenofovir disoproxil (TDF) or entecavir (ETV) has been shown to reduce the risk of hepatocellular carcinoma (HCC) and mortality. However, controversy exists regarding if one treatment is better than the other.</span></p>

<div><p><b>Background:</p> </b><p><strong> </strong>Infections with multidrug-resistant organisms (MDR) are a common cause of organ failures and increased fatality in patients with cirrhosis. Sepsis is associated with increased oxidative stress with widespread endothelial, cellular injury and acute deficiency of vitamin C. Polymyxins used for <span>MDR infections have increased incidence of nephrotoxicity.

<div><p><b>Background: </b>Liver cancer poses a significant health challenge worldwide, but its burden in low Socio-Demographic Index (SDI) countries remains understudied. These countries face unique obstacles, including limited healthcare resources, inadequate screening programs, and a higher prevalence of risk factors like hepatitis B and C. Liver cancer has become a pressing public health issue, impacting individuals, communities, and healthcare systems in low SDI countries.